HIGH-VOLUME · SEX-BALANCED
liraglutide Side Effects
liraglutide (also sold as Victoza, Saxenda) is HIGH-VOLUME in this FAERS book #144 of 524 by FAERS report count. Signature opener: SEX-BALANCED - 64% of sex-coded reports are female (28,938 F / 16,113 M).
Data updated 2026-05-15
- 47,843
- FAERS reports
FAERS voluntary reports, 2004 to 2025. High volume tracks exposure and reporting culture; see methodology for de-dup rules.
liraglutide reporting skew - 64% of sex-coded reports are female (28,938 F / 16,113 M). Volume band HIGH-VOLUME #144 of 524 by FAERS report count; caseload CASELOAD.
High-report extract for liraglutide (Victoza): 47,843 FAERS rows (2004-2025). Top named reactions: NAUSEA, BLOOD GLUCOSE INCREASED, VOMITING. Outcome stamps DEATH-MARKED · HOSP-MID · SEX-BALANCED. FAERS is voluntary signal detection, not incidence.
Counts from the openFDA FAERS extract (2004–2025). Stamps CASELOAD · DEATH-MARKED · HOSP-MID · SEX-BALANCED.
NAUSEA leads 7,005 of 47,843 reports
Who reports · age peak 45-64 (SEX-BALANCED)
Sex coding · SEX-BALANCED
Age peak 45-64 (15,372 reports)
FAERS filings rising toward 2025
Reactions in Death Reports
Death appears on 1,745 reports (3.6% - MARKED). Reactions below co-occur in those rows only.
| Reaction | Reports |
|---|---|
| PANCREATIC CARCINOMA | 460 |
| DEATH | 435 |
| PANCREATIC CARCINOMA METASTATIC | 173 |
| DYSPNOEA | 84 |
| METASTASES TO LIVER | 81 |
| ACUTE KIDNEY INJURY | 74 |
| PULMONARY EMBOLISM | 71 |
| ANXIETY | 70 |
| HYPOTHYROIDISM | 70 |
| RENAL FAILURE | 63 |
| ARTERIOSCLEROSIS | 60 |
| NAUSEA | 60 |
| CONDITION AGGRAVATED | 59 |
| PAIN IN EXTREMITY | 59 |
| HYPOXIA | 58 |
| THROMBOSIS | 58 |
| ASTHMA | 57 |
| PULMONARY FIBROSIS | 57 |
| NODULE | 56 |
| LUNG DISORDER | 55 |
Reactions in Hospitalization Reports
Hospitalization mid-share (10,464, 21.9%). Co-reported reactions:
| Reaction | Reports |
|---|---|
| PANCREATITIS | 1,046 |
| NAUSEA | 1,017 |
| VOMITING | 935 |
| DIARRHOEA | 664 |
| ACUTE KIDNEY INJURY | 555 |
| PANCREATITIS ACUTE | 516 |
| DEHYDRATION | 498 |
| ABDOMINAL PAIN | 468 |
| DYSPNOEA | 428 |
| DIABETIC KETOACIDOSIS | 423 |
| BLOOD GLUCOSE INCREASED | 412 |
| WEIGHT DECREASED | 381 |
| FALL | 318 |
| DECREASED APPETITE | 303 |
| DIZZINESS | 289 |
| ASTHENIA | 287 |
| CONSTIPATION | 279 |
| FATIGUE | 274 |
| MALAISE | 273 |
How to read liraglutide FAERS figures (CASELOAD · DEATH-MARKED · HOSP-MID)
FAERS holds 47,843 voluntary reports linked to liraglutide (Victoza, Saxenda), 2004-2025. Death is listed on 1,745 (3.6%). Hospitalization appears on 10,464 (21.9%). Top co-reported indication: Type 2 Diabetes Mellitus.
CASELOAD books overweight common drugs and loud reporting cultures; SEX-BALANCED is the page opener, not a per-patient risk.
Read with liraglutide
Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-MARKED · HOSP-MID stamps.
ABS(total_reports) peer at 47,788 FAERS cases (Δ 55 lighter vs liraglutide); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's CASELOAD · DEATH-MARKED · HOSP-MID · SEX-BALANCED.
ABS(total_reports) peer at 48,091 FAERS cases (Δ 248 heavier vs liraglutide); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's CASELOAD · DEATH-MARKED · HOSP-MID · SEX-BALANCED.
ABS(total_reports) peer at 47,513 FAERS cases (Δ 330 lighter vs liraglutide); DEATH-MARKED · HOSP-LIGHT · SEX-BALANCED vs this page's CASELOAD · DEATH-MARKED · HOSP-MID · SEX-BALANCED.
ABS(total_reports) peer at 47,426 FAERS cases (Δ 417 lighter vs liraglutide); DEATH-HEAVY · HOSP-MID · FEMALE-LED vs this page's CASELOAD · DEATH-MARKED · HOSP-MID · SEX-BALANCED.
ABS(death_share) pole at 62.1% death-mentioned reports (Δ 58.5 pp vs liraglutide's DEATH-MARKED): CASELOAD · HOSP-MID.
liraglutide sits in CASELOAD; high report volume tracks exposure and reporting culture more than per-patient risk. Methodology states the de-dup rules.